Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Early IL-2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMN-dominating response and reduced lung pathology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A case of false-positive pneumococcal urinary antigen test in a bacteremic Streptococcus agalactiae infection

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Nephrotic syndrome and pulmonary hypertension as complications of intravenous drug abuse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Oral symptoms and pathologies in Danish patients with chronic kidney disease- a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic Carcinoma: An International Delphi Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reply to Firkins and Krishna

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Response

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

OriginalsprogEngelsk
TidsskriftAPMIS - Journal of Pathology, Microbiology and Immunology
Vol/bind127
Udgave nummer1
Sider (fra-til)27-32
Antal sider6
ISSN0903-4641
DOI
StatusUdgivet - jan. 2019

ID: 55881671